MF
JSPR icon

Magnetar Financial’s Jasper Therapeutics JSPR Stock Holding History

Magnetar Financial’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,825
Closed -$381 – 1416
2021
Q2 		$381 Buy
+3,825
New +$380K ﹤0.01% 965

Other funds holding JSPR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Magnetar Financial's JSPR Position: Q3 2021 in Review

Magnetar Financial sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 3,825 shares — an estimated $381 sold.

Magnetar Financial first reported a position in JSPR in Q2 2021 and held it in 1 quarter. The position peaked at $381 in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • Magnetar Financial reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Magnetar Financial sold 3,825 Jasper Therapeutics shares in Q3 2021, an estimated $381.
  • Magnetar Financial first reported a position in Jasper Therapeutics in Q2 2021 and held it in 1 quarter.
  • Magnetar Financial's Jasper Therapeutics position peaked at $381 in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Magnetar Financial's 13F filing for Q3 2021, filed 12 Nov 2021.